journal
MENU ▼
Read by QxMD icon Read
search

Prostate

journal
https://www.readbyqxmd.com/read/29774590/heritage-of-stanislaw-ciechanowski-1869-1945-discoverer-of-pathogenesis-of-prostatic-hyperplasia-passionis-insignia-signis-fulgent-mirificis
#1
Andrzej Wincewicz, Piotr Woltanowski, Stanisław Sulkowski
BACKGROUND: Prostatic enlargement was first correctly recognized as a prostatic hyperplasia by professor of anatomic pathology, Stanisław Ciechanowski (1869-1945) in Cracow on contrary to Parisian urologist Jean Casimir Félix Guyon's concepts of progressing atherosclerosis as a morphological cause of prostatic overgrowth and mechanical insufficiency of lower urinary tract. METHODS: Primary resources were analyzed about Stanisław Ciechanowski mainly from depositories of the Section of Special Collection, Stanisław Konopka Main Medical Library Warsaw and Polish bibliograhy of Estreichers at Jagiellonian University...
May 18, 2018: Prostate
https://www.readbyqxmd.com/read/29761525/ets2-is-a-prostate-basal-cell-marker-and-is-highly-expressed-in-prostate-cancers-aberrantly-expressing-p63
#2
Alba Torres, Mohammed Alshalalfa, Elai Davicioni, Anuj Gupta, Srinivasan Yegnasubramanian, Sarah J Wheelan, Jonathan I Epstein, Angelo M De Marzo, Tamara L Lotan
BACKGROUND: Rare prostate carcinomas aberrantly express p63 and have an immunophenotype intermediate between basal and luminal cells. Here, we performed gene expression profiling on p63-expressing prostatic carcinomas and compared them to usual-type adenocarcinoma. We identify ETS2 as highly expressed in p63-expressing prostatic carcinomas and benign prostate basal cells, with lower expression in luminal cells and primary usual-type adenocarcinomas. METHODS: A total of 8 p63-expressing prostate carcinomas at radical prostatectomy were compared to 358 usual-type adenocarcinomas by gene expression profiling performed on formalin fixed paraffin embedded tumor tissue using Affymetrix 1...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29761524/the-24th-annual-prostate-cancer-foundation-scientific-retreat-report
#3
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5-7, 2017, at the Omni Shoreham Hotel in Washington, DC. METHODS: The PCF Scientific Retreat is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances in prostate cancer biology and treatment. RESULTS: Themes highlighted at this year's meeting included: (i) new understandings in prostate cancer biology and disease progression; (ii) new mechanisms and treatment targets in advanced prostate cancer; (iii) advances in precision medicine genomics, germline genetics, and selection of targeted therapies; (iv) PSMA-targeted agents for PET imaging and radionuclide therapy; (v) approaches for improving the efficacy of immunotherapy in prostate cancer; (vi) applications of 3D Genomics in prostate cancer research; and (vii) potential applications of artificial intelligence in prostate cancer...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29761522/thrombotic-characteristics-of-extracellular-vesicles-derived-from-prostate-cancer-cells
#4
Hassan A Al Saleh, Sandor Haas-Neill, Ali Al-Hashimi, Anil Kapoor, Bobby Shayegan, Richard C Austin, Khalid Al-Nedawi
BACKGROUND: Prostate cancer (PC) patients in advanced stages of the disease have high risk of blood coagulation complications. The procoagulant molecule Tissue factor (TF), and the fibrinolysis inhibitor plasminogen activator inhibitor-1 PAI-1 play important role in this complication. Extracellular vesicles (EV) shed from cancer cells may contribute to the regulation of TF and PAI-1. The procoagulant activity of EV can be associated with the oncogenic and metastatic characteristics of their cells...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29749077/cabazitaxel-regimens-inhibit-the-growth-of-prostate-cancer-cells-and-enhances-the-anti-tumor-properties-of-pedf-with-various-efficacy-and-toxicity
#5
Courtney Jarvis, Thomas Nelius, Dalia Martinez-Marin, Souad R Sennoune, Stéphanie Filleur
BACKGROUND: Taxanes chemotherapies represent the major therapeutic alternative for symptomatic mCRPC. While docetaxel is the most commonly prescribed Taxane for mCRPC; cabazitaxel has been approved for patients unresponsive to docetaxel. Still mCRPC remains incurable and patients often experience severe side effects. Recently, the FIRSTANA trial first demonstrated the absence of superiority in overall survival between cabazitaxel and docetaxel in mCRPC patients. Inversely, different toxicity were reported suggesting that cabazitaxel may provide a first line treatment option for some patients urging for a deeper characterization of cabazitaxel mechanisms of action as well as a re-evaluation of cabazitaxel conventional dose and schedule...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29748961/growth-hormone-releasing-hormone-receptor-antagonists-modify-molecular-machinery-in-the-progression-of-prostate-cancer
#6
Laura Muñoz-Moreno, Andrew V Schally, Juan C Prieto, M José Carmena, Ana M Bajo
BACKGROUND: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. METHODS: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29748958/functional-roles-and-potential-clinical-application-of-mirna-345-5p-in-prostate-cancer
#7
Ilker Tinay, Mingyue Tan, Bin Gui, Lillian Werner, Adam S Kibel, Li Jia
BACKGROUND: MicroRNAs (miRNAs) are small non-coding RNAs, which negatively regulate gene expression and impact prostate cancer (PCa) growth and progression. Circulating miRNAs are stable and detectable in cell-free body fluids, such as serum. Investigation of circulating miRNAs presents great potential in uncovering new insights into the roles of miRNAs in PCa diagnosis and therapy. METHODS: Using TaqMan miRNA quantitative reverse transcription polymerase chain reaction (RT-qPCR), we compared the expression levels of five miRNAs (miR-193a-3p, miR-9-3p, miR-335-5p, miR-330-3p, and miR-345-5p) in serum samples from 20 normal individuals without cancer, 25 patients with localized disease, 25 patients with hormone-naïve or hormone sensitive metastatic disease, and 25 patients with metastatic castration-resistant prostate cancer (CRPC)...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29740846/prostatic-collagen-architecture-in-neutered-and-intact-canines
#8
Hannah Ruetten, Kyle A Wegner, Michael F Romero, Michael W Wood, Paul C Marker, Douglas Strand, Sara A Colopy, Chad M Vezina
BACKGROUND: Prostate stiffness and increased collagen content both associate with the presence of urinary symptoms in men but mechanisms responsible, including impact of age and androgens, are unknown. Dogs develop prostate-related urinary dysfunction similar to humans, but mechanisms are also unknown. Mice have been used to examine how prostatic collagen accumulation affects voiding but whether mouse prostatic collagen organization resembles human or dog has not been evaluated. Here, we have constructed the first comprehensive, comparative maps of collagen architecture in canine, human, and mouse prostate and test whether canine prostatic collagen content is increased by aging and reduced by castration...
May 8, 2018: Prostate
https://www.readbyqxmd.com/read/29717502/statin-use-high-cholesterol-and-prostate-cancer-progression-results-from-hcap-nc
#9
Emma H Allott, Laura Farnan, Susan E Steck, Lixin Song, Lenore Arab, L Joseph Su, Elizabeth T H Fontham, James L Mohler, Jeannette T Bensen
BACKGROUND: Statin use is associated with lower advanced prostate cancer risk and reduced prostate cancer-specific mortality, but prior studies were conducted mainly in white men. We examined the effect of statin use on risk of prostate cancer progression in a population-based, minority-enriched cohort. METHODS: We used data from prostate cancer cases (45% African American) diagnosed between 2004 and 2007 who participated in the Health Care Access and Prostate Cancer Treatment in North Carolina cohort (HCaP-NC)...
May 1, 2018: Prostate
https://www.readbyqxmd.com/read/29717499/meeting-report-from-the-prostate-cancer-foundation-psma-directed-radionuclide-scientific-working-group
#10
REVIEW
Andrea K Miyahira, Kenneth J Pienta, Michael J Morris, Neil H Bander, Richard P Baum, Wolfgang P Fendler, William Goeckeler, Michael A Gorin, Hartwig Hennekes, Martin G Pomper, Oliver Sartor, Scott T Tagawa, Scott Williams, Howard R Soule
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents...
May 1, 2018: Prostate
https://www.readbyqxmd.com/read/29707793/interleukin-6-induces-vegf-secretion-from-prostate-cancer-cells-in-a-manner-independent-of-androgen-receptor-activation
#11
Kenichiro Ishii, Takeshi Sasaki, Kazuhiro Iguchi, Shinya Kajiwara, Manabu Kato, Hideki Kanda, Yoshifumi Hirokawa, Kiminobu Arima, Atsushi Mizokami, Yoshiki Sugimura
BACKGROUND: The reduced androgen-sensitivity of prostate cancer (PCa) cells is an important clinical development because of its association with the cells' progression to castration-resistant prostate cancer (CRPC). During androgen deprivation therapy (ADT), stroma-derived growth factors and cytokines can activate the androgen receptor (AR). For example, IL-6 is a multifunctional cytokine that is involved in the malignancy of PCa cells through AR activation. In the present study, we used an androgen-sensitive human PCa cell line (LNCaP) and its sublines to investigate the relationship between the responsiveness of PCa cells to IL-6 treatment and the cellular AR signaling pathway...
April 29, 2018: Prostate
https://www.readbyqxmd.com/read/29707790/time-of-metastatic-disease-presentation-and-volume-of-disease-are-prognostic-for-metastatic-hormone-sensitive-prostate-cancer-mhspc
#12
Edoardo Francini, Kathryn P Gray, Wanling Xie, Grace K Shaw, Loana Valença, Brandon Bernard, Laurence Albiges, Lauren C Harshman, Philip W Kantoff, Mary-Ellen Taplin, Cristopher J Sweeney
BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition, mHSPC, and those who relapse after prior local therapy (PLT) have longer overall survival (OS) compared to high volume (HV) and de-novo (DN), respectively. Using a hospital-based registry, we aimed to assess whether a classification based on time of metastatic disease (PLT vs DN) and disease volume (LV vs HV) are prognostic for mHSPC pts treated with ADT...
April 29, 2018: Prostate
https://www.readbyqxmd.com/read/29682763/differential-expression-of-annexin-2-spink1-and-hsp60-predict-progression-of-prostate-cancer-through-bifurcated-who-gleason-score-categories-in-african-american-men
#13
Desta A Beyene, Tammey J Naab, Norma F Kanarek, Victor Apprey, Ashwini Esnakula, Farahan A Khan, Marc R Blackman, Collis A Brown, Tamaro S Hudson
BACKGROUND: Although studies have observed several markers correlate with progression of prostate cancer (PCa), no specific markers have been identified that accurately predict the progression of this disease, even in African American (AA) men who are generally at higher risk than other ethnic groups. The primary goal of this study was to explore whether three markers could predict the progression of PCa. METHOD: We investigated protein expression of Annexin 2 (ANX2), serine peptidase inhibitor, kazal type 1(SPINK1)/tumor-associated trypsin inhibitor (TATI), and heat shock protein 60 (Hsp60) in 79 archival human prostate trans-rectal ultrasound (TRUS) biopsy tissues according to a modified World Health Organization (WHO) classification: normal (WHO1a), Gleason Score (GS6 (WHO1b), GS7 subgroups (WHO2 = 3 + 4, WHO3 = 4 + 3), GS8 (WHO4), and GS9-10 (WHO5)...
April 22, 2018: Prostate
https://www.readbyqxmd.com/read/29671889/two-long-non-coding-rnas-prcat17-3-and-prcat38-could-efficiently-discriminate-benign-prostate-hyperplasia-from-prostate-cancer
#14
Hamid Bayat, Behzad Narouie, Seyed-Amir Mohsen Ziaee, Seyed Javad Mowla
BACKGROUND: Long non-coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer-associated lncRNAs has been listed via RNA-seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities to discriminate prostate tumors from benign prostate hyperplasia (BPH). METHODS: Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses...
April 19, 2018: Prostate
https://www.readbyqxmd.com/read/29667217/secondary-prostate-cancer-screening-outcomes-by-race-in-the-prostate-lung-colorectal-and-ovarian-plco-screening-trial
#15
Eric A Miller, Paul F Pinsky, Amanda Black, Gerald L Andriole, Dudith Pierre-Victor
BACKGROUND: Despite disparities in prostate cancer incidence and mortality rates between black and white men, there is still insufficient data available to assess potential differences in the benefits and harms of prostate cancer screening by race. Although the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial is underpowered to detect a difference by race in prostate-cancer specific mortality, because of the large study size, there are still sufficient numbers to examine secondary screening outcomes...
April 17, 2018: Prostate
https://www.readbyqxmd.com/read/29663462/survival-benefit-of-local-versus-no-local-treatment-for-metastatic-prostate-cancer-impact-of-baseline-psa-and-metastatic-substages
#16
Raisa S Pompe, Derya Tilki, Felix Preisser, Sami-Ramzi Leyh-Bannurah, Marco Bandini, Michele Marchioni, Philipp Gild, Zhe Tian, Nicola Fossati, Luca Cindolo, Shahrokh F Shariat, Hartwig Huland, Markus Graefen, Alberto Briganti, Pierre I Karakiewicz
BACKGROUND: To test whether local treatment (LT), namely radical prostatectomy (RP) or brachytherapy (BT) still confers a survival benefit versus no local treatment (NLT), when adjusted for baseline PSA (bPSA). To further examine whether the effect of LT might be modulated according to bPSA and M1 substages. METHODS: Of 13 906 mPCa patients within the SEER (2004-2014), 375 underwent RP, 175 BT, and 13 356 NLT. Multivariable competing risks regression (MVA CRR) analyses after 1:2 propensity score matching assessed the impact of LT versus NLT on cancer specific mortality (CSM)...
April 16, 2018: Prostate
https://www.readbyqxmd.com/read/29659051/psa-alpha-2-macroglobulin-complex-is-enzymatically-active-in-the-serum-of-patients-with-advanced-prostate-cancer-and-can-degrade-circulating-peptide-hormones
#17
Maya B Kostova, William Nathaniel Brennen, David Lopez, Lizamma Anthony, Hao Wang, Elizabeth Platz, Samuel R Denmeade
BACKGROUND: Prostate cancer cells produce high levels of the serine protease Prostate-Specific Antigen (PSA). PSA is enzymatically active in the tumor microenvironment but is presumed to be enzymatically inactive in the blood due to complex formation with serum protease inhibitors α-1-antichymotrypsin and α-2-macroglobulin (A2M). PSA-A2M complexes cannot be measured by standard ELISA assays and are also rapidly cleared from the circulation. Thus the exact magnitude of PSA production by prostate cancer cells is not easily measured...
April 16, 2018: Prostate
https://www.readbyqxmd.com/read/29655297/understanding-of-multigene-test-results-among-males-undergoing-germline-testing-for-inherited-prostate-cancer-implications-for-genetic-counseling
#18
Veda N Giri, Elias Obeid, Sarah E Hegarty, Laura Gross, Lisa Bealin, Colette Hyatt, Carolyn Y Fang, Amy Leader
BACKGROUND: Genetic testing (GT) for prostate cancer (PCA) is rising, with limited insights regarding genetic counseling (GC) needs of males. Genetic Evaluation of Men (GEM) is a prospective multigene testing study for inherited PCA. Men undergoing GC were surveyed on knowledge of cancer risk and genetics (CRG) and understanding of personal GT results to identify GC needs. METHODS: GEM participants with or high-risk for PCA were recruited. Pre-test GC was in-person, with video and handout, or via telehealth...
April 14, 2018: Prostate
https://www.readbyqxmd.com/read/29654614/quercetin-protects-against-chronic-prostatitis-in-rat-model-through-nf-%C3%AE%C2%BAb-and-mapk-signaling-pathways
#19
Ling-Quan Meng, Fei-Ya Yang, Ming-Shuai Wang, Ben-Kang Shi, De-Xi Chen, Dong Chen, Qiang Zhou, Qing-Bao He, Lin-Xiang Ma, Wen-Long Cheng, Nian-Zeng Xing
BACKGROUND: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a common disease of urology, of which the pathogenesis and therapy remain to be further elucidated. Quercetin has been reported to improve the symptoms of CP/CPPS patients. We aimed to verify the therapeutic effect of quercetin on CP/CPPS and identify the mechanism responsible for it. METHODS: A novel CP/CPPS model induced with Complete Freund Adjuvant in Sprague Dawley rats was established and the prostates and blood specimens were harvested for further measurement after oral administration of quercetin for 4 weeks...
April 13, 2018: Prostate
https://www.readbyqxmd.com/read/29635810/earlier-use-of-androgen-receptor-axis-targeted-drugs-may-improve-overall-survival-in-patients-with-non-metastatic-castration-resistant-prostate-cancer
#20
Keiichiro Mori, Takahiro Kimura, Kagenori Ito, Hajime Onuma, Masatoshi Tanaka, Taishi Matsuura, Gaku Kurokawa, Kosuke Iwatani, Yuzo Inaba, Keigo Sakanaka, Hiroshi Sasaki, Jun Miki, Tatsuya Shimomura, Kenta Miki, Shin Egawa
BACKGROUND: To evaluate the role of androgen receptor-axis-targeted drugs (ARAT) in non-metastatic castration-resistant prostate cancer (nmCRPC) versus mCRPC. METHODS: Chemotherapy-naive patients (n = 114) with CRPC who had no metastasis at the time of diagnosis were included in this retrospective study. All patients were treated with ARAT at Jikei University and its affiliated hospitals from July 2014 to March 2017. The patients were stratified into nmCRPC (n = 81) and mCRPC (n = 33) groups according to their metastatic status at ARAT induction...
April 10, 2018: Prostate
journal
journal
20232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"